Gordius

Gordius is a prescription oral medication that contains the active ingredient gabapentin, an anticonvulsant classified under ATC code N03AX12. Marketed in the European Union, Gordius is supplied without a specified strength in this description and is intended for use under medical supervision. It is prescribed for conditions such as epilepsy, postherpetic neuralgia, and other neuropathic pain syndromes after clinical assessment and individualized treatment planning by the physician.

Gordius is indicated for several neurological and pain-related conditions where gabapentin therapy is appropriate.

- Epilepsy as adjunctive therapy for partial seizures. - Postherpetic neuralgia to alleviate chronic pain following shingles. - Diabetic peripheral neuropathy and other neuropathic pain states. - Restless legs syndrome when other treatments are insufficient. - Off‑label use may include fibromyalgia or anxiety disorders under specialist guidance. - Adjunctive treatment for focal onset seizures in adults. - Management of chronic cough associated with neuropathic mechanisms. - Adjunctive therapy for migraine prophylaxis when other agents are ineffective.

The safety profile of Gordius reflects the typical effects observed with gabapentin, ranging from mild, frequently reported events to rare but serious reactions.

Common: - Dizziness or light‑headed feeling. - Somnolence or fatigue. - Peripheral edema, especially in the lower extremities. - Visual disturbances such as blurred vision. - Nausea, vomiting, or abdominal discomfort. - Dry mouth or increased salivation. - Weight gain or loss.

Serious: - Severe allergic reactions, including rash, Stevens‑Johnson syndrome, or facial swelling. - Mood changes, depression, or suicidal thoughts. - Respiratory depression when combined with central depressants. - Unusual muscle weakness or coordination problems. - Seizure exacerbation in patients with uncontrolled epilepsy. - Hepatic dysfunction indicated by elevated liver enzymes.

When prescribing Gordius, clinicians should evaluate patient history and monitor for conditions that may increase risk of adverse outcomes.

- Renal impairment requires dose adjustment because gabapentin is excreted unchanged. - Caution in patients with a history of depression or suicidal ideation. - Avoid abrupt discontinuation to prevent withdrawal symptoms such as anxiety or seizures. - Use carefully in the elderly due to increased sensitivity to dizziness and falls. - Assess for hypersensitivity reactions before initiating therapy. - Pregnancy and lactation safety have not been established; discuss risks with a healthcare provider.

Gordius may interact with other medicines, affecting its concentration or the effect of co‑administered drugs.

Avoid: - Antacids containing aluminum or magnesium, which can reduce gabapentin absorption. - Opioids such as morphine or oxycodone, which may increase central nervous system depression. - Alcohol, because combined use can enhance sedation and dizziness. - Cimetidine, which can increase gabapentin plasma concentrations. - Proton pump inhibitors, which may modestly affect gabapentin bioavailability.

Use with caution: - CNS depressants including benzodiazepines, barbiturates, or antihistamines. - Diuretics that may affect renal clearance of gabapentin. - Anticonvulsants like carbamazepine that may alter gabapentin levels. - Pregabalin or other gabapentinoids, as combined use may increase side‑effects.